GLP-1 medications — including Ozempic, Wegovy, Mounjaro, and Zepbound — have become some of the most talked-about drugs in the country. Originally developed for Type 2 diabetes, these medications have shown remarkable effectiveness for weight loss, cardiovascular risk reduction, and other conditions. If you are enrolled in Medicare and wondering whether your plan covers any of these drugs, the answer depends on why you need the medication, which specific drug your doctor prescribes, and what Part D plan you have.
This guide breaks down which GLP-1 drugs Medicare may cover, what conditions qualify, how much you might pay, and what new programs are launching in 2026 that could expand access.
Understanding GLP-1 Medications
GLP-1 receptor agonists (and related dual-agonist drugs) work by mimicking hormones that regulate blood sugar, appetite, and metabolism. There are several brand-name medications in this class, each approved by the FDA for different uses:
Semaglutide
- Ozempic (injectable) — FDA-approved for Type 2 diabetes management and to reduce the risk of major cardiovascular events in adults with Type 2 diabetes and established cardiovascular disease.
- Rybelsus (oral tablet) — FDA-approved for Type 2 diabetes management. This is an oral form of semaglutide, though it generally produces less weight loss than the injectable versions.
- Wegovy (injectable and oral tablet) — FDA-approved for chronic weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition. Wegovy also carries an FDA-approved indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are overweight or obese.
Tirzepatide
- Mounjaro (injectable) — FDA-approved for Type 2 diabetes management. Tirzepatide is a dual GIP/GLP-1 receptor agonist.
- Zepbound (injectable) — FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Zepbound also has an FDA-approved indication for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
The distinction between these drugs matters for Medicare coverage because the approved indication — diabetes, cardiovascular risk reduction, sleep apnea, or weight loss — determines whether Part D can pay for it.
The Federal Weight-Loss Drug Exclusion
Here is the core issue: federal law prohibits Medicare Part D plans from covering drugs when they are prescribed solely for weight loss or cosmetic purposes. This exclusion dates back to the Medicare Prescription Drug, Improvement and Modernization Act of 2003 and was influenced by safety concerns about diet pills from the 1990s.
This means that even though Wegovy and Zepbound are FDA-approved weight-loss medications, no Part D plan — whether a standalone prescription drug plan or a Medicare Advantage plan with drug coverage — is permitted to cover them if the only reason for the prescription is to lose weight.
However, that does not mean these drugs are never covered. Several of these medications have FDA-approved uses beyond weight management, and Medicare Part D may cover them for those purposes.
What Medicare Part D Currently Covers
Medicare Part D may cover GLP-1 medications when they are prescribed for an approved medical condition other than weight loss. Here is a breakdown by drug:
Ozempic (Semaglutide)
Part D plans may cover Ozempic when prescribed for Type 2 diabetes or to reduce cardiovascular risk in patients with Type 2 diabetes and established heart disease. Ozempic is one of the more widely covered GLP-1 drugs, appearing on the formularies of the majority of Part D plans. However, coverage is not guaranteed — your plan must list it on its Drug List (formulary), and you will likely need to meet specific requirements.
Rybelsus (Semaglutide — Oral)
Part D plans may cover Rybelsus for Type 2 diabetes management. As an oral tablet, it may be an option for beneficiaries who prefer not to use injections, though it may produce less dramatic weight-loss effects compared to injectable semaglutide.
Mounjaro (Tirzepatide)
Part D plans may cover Mounjaro for Type 2 diabetes management. More than 90% of Part D plans include Mounjaro on their formularies. It is not covered for weight loss.
Wegovy (Semaglutide)
This is where coverage gets nuanced. Part D plans may cover Wegovy when prescribed to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are overweight or obese. Some plans may also cover it for metabolic-associated steatohepatitis (MASH). Wegovy is not covered under standard Part D when prescribed solely for weight loss.
Zepbound (Tirzepatide)
Part D plans may cover Zepbound when prescribed for the treatment of moderate to severe obstructive sleep apnea in adults with obesity. It is not covered for weight management alone.
Formulary Tiers and What You May Pay
When a GLP-1 medication is covered by your Part D plan, your out-of-pocket cost depends on where it falls on your plan's formulary tier. Most Part D formularies organize drugs into tiers, with lower tiers generally meaning lower costs:
- Tier 1–2: Typically generic drugs with low copays.
- Tier 3: Preferred brand-name drugs.
- Tier 4: Non-preferred brand-name drugs.
- Tier 5: Specialty-tier drugs (usually the most expensive).
GLP-1 medications like Ozempic and Mounjaro are typically placed on Tier 3 or Tier 4 (preferred or non-preferred brand), while some plans may classify them as specialty-tier (Tier 5) drugs. This means copays may range from roughly $25 to $150 or more per month during the initial coverage phase, depending on your plan's cost-sharing structure.
How Part D Cost-Sharing Works in 2026
The Part D benefit has three main phases:
- Deductible: You pay the full cost of your drugs until you meet the maximum deductible of $615 for 2026. Some plans have lower deductibles, and some waive the deductible for certain drug tiers.
- Initial Coverage Phase: After meeting your deductible, you generally pay 25% coinsurance (or a flat copay, depending on your plan) until your total out-of-pocket spending reaches the annual cap.
- Catastrophic Coverage: Once your out-of-pocket costs reach $2,100 for the year, you pay $0 for the rest of the year. The former "donut hole" coverage gap has been eliminated.
For expensive GLP-1 medications, it is possible to reach the $2,100 annual out-of-pocket cap within the first few months of the year. After that point, your Part D plan and Medicare cover the full cost for the remainder of the year. If you prefer to avoid large upfront costs, the Medicare Prescription Payment Plan lets you spread your out-of-pocket costs into monthly installments throughout the year at no interest.
Prior Authorization and Step Therapy
Even when a GLP-1 drug appears on your plan's formulary, your plan may require additional steps before it will approve coverage:
- Prior authorization: Your doctor must submit documentation showing that the medication is medically necessary for a covered condition (such as Type 2 diabetes or cardiovascular risk reduction). Simply calling your plan and asking if a drug is "covered" may give you a misleading answer — coverage often depends on meeting specific clinical criteria.
- Step therapy: Some plans require you to try less expensive medications first. For example, you may need to demonstrate that you have tried metformin or another first-line diabetes drug before your plan will approve Ozempic or Mounjaro.
- Quantity limits: Plans may restrict how much of the drug you can fill during a given time period.
If your prior authorization is denied, you have the right to appeal. Your doctor can submit additional clinical documentation to support the medical necessity of the medication. You may also contact your State Health Insurance Assistance Program (SHIP) for free, unbiased help navigating the appeals process.
The Medicare GLP-1 Bridge Program (July–December 2026)
In a significant development, CMS announced the Medicare GLP-1 Bridge — a short-term demonstration program that will operate from July 1, 2026, through December 31, 2026. This program, for the first time, provides a pathway for Medicare beneficiaries to access GLP-1 drugs specifically for weight reduction.
Which Drugs Are Covered
The GLP-1 Bridge covers Wegovy (both injection and oral tablet formulations) and Zepbound when used to reduce excess body weight alongside lifestyle modifications.
Note that Ozempic and Mounjaro are not included in the Bridge program, since those drugs are not FDA-approved for weight management. They remain covered under standard Part D rules for diabetes and other approved uses.
Eligibility Requirements
To qualify for the Medicare GLP-1 Bridge, a healthcare provider must certify that the beneficiary:
- Is at least 18 years of age, and
- Meets one of the following clinical criteria:
- BMI of 35 or higher, OR
- BMI of 30 or higher with at least one of the following: heart failure with preserved ejection fraction, uncontrolled hypertension (systolic above 140 or diastolic above 90 while on two antihypertensive medications), or chronic kidney disease stage 3a or above, OR
- BMI of 27 or higher with at least one of the following: pre-diabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease
Cost to Beneficiaries
Eligible beneficiaries will pay a $50 copay per fill. This $50 amount remains the same regardless of what phase of the Part D benefit you are in — whether you have met your deductible or not.
How to Access the Program
Prior authorization requests will be submitted by your healthcare provider to a central processor managed by CMS, not through your individual Part D plan. CMS has indicated that additional details about how to enroll and access the program will be published in Spring 2026. You can check for updates at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227).
Who Can Participate
The program is nationwide and available in all states and territories. You must be enrolled in a standalone Part D prescription drug plan or a Medicare Advantage plan with drug coverage to participate.
The BALANCE Model (Starting January 2027)
The Medicare GLP-1 Bridge is intended to serve as a transition to a longer-term program called the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth). Beginning in January 2027, participating Part D plan sponsors will be able to cover GLP-1 medications for weight management through this voluntary, five-year model.
Key features of the BALANCE Model include:
- Negotiated drug pricing: CMS will negotiate pricing with GLP-1 manufacturers on behalf of participating plans.
- Lifestyle support: Beneficiaries receiving GLP-1s for weight management will be offered access to a lifestyle support program at no additional cost.
- Voluntary participation: Part D plans must opt in. Not all plans will participate, so if maintaining GLP-1 access for weight management is important to you, you may want to confirm whether your plan is participating during the fall enrollment period for 2027.
- Model duration: The BALANCE Model is scheduled to run through December 2031 unless extended.
If you are enrolled in the GLP-1 Bridge program during the second half of 2026, you will need to enroll in a Part D plan that participates in the BALANCE Model for 2027 to continue receiving coverage for weight-management GLP-1s without interruption.
Original Medicare vs. Medicare Advantage: Does It Matter?
Whether you are enrolled in Original Medicare with a standalone Part D plan or a Medicare Advantage plan with drug coverage (MA-PD), the same federal rules apply to GLP-1 coverage:
- The statutory exclusion of weight-loss drugs applies equally to both.
- Both types of plans may cover GLP-1s for approved medical uses such as diabetes or cardiovascular risk reduction, depending on each plan's formulary.
- Both types of plans are eligible for the Medicare GLP-1 Bridge program and the upcoming BALANCE Model.
The key differences are in the specific formulary each plan uses and the cost-sharing structure (copays, coinsurance, and deductible amounts). Two plans may both cover Ozempic for Type 2 diabetes, but one may place it on a preferred tier with a $40 copay while another places it on a specialty tier with 25% coinsurance. When comparing plans, it is important to use the plan's Drug List tool — available on Medicare.gov — to look up your specific medication and see what you would pay.
Medicare Advantage plans may also offer supplemental benefits such as nutrition counseling or fitness programs that could complement GLP-1 treatment, though these vary by plan and region.
What If You Cannot Get Coverage?
If you need a GLP-1 medication and your Part D plan does not cover it for your condition, there are several steps you may consider:
- Ask your doctor about covered indications. If you have Type 2 diabetes and your doctor prescribes Ozempic for blood sugar control, your plan may cover it even though it would not cover it for weight loss.
- File an appeal or exception request. If your plan denies coverage, your doctor can submit a coverage determination request or appeal with supporting clinical documentation.
- Check the manufacturer's website for any patient assistance programs. Novo Nordisk (maker of Ozempic, Rybelsus, and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) may offer savings programs, though eligibility and availability for Medicare beneficiaries may vary.
- Wait for the GLP-1 Bridge. If you meet the clinical eligibility criteria, the Bridge program launching in July 2026 may provide a path to coverage at $50 per month.
- Contact SHIP. Your State Health Insurance Assistance Program offers free counseling and can help you understand your options. Find your local SHIP at shiphelp.org or by calling 1-800-MEDICARE.
Key Takeaways
- Medicare Part D may cover Ozempic and Mounjaro for Type 2 diabetes, and Wegovy for cardiovascular risk reduction — but not for weight loss under the standard benefit.
- Zepbound may be covered for obstructive sleep apnea in adults with obesity.
- Federal law currently prohibits Part D from covering drugs prescribed solely for weight management.
- The Medicare GLP-1 Bridge program (July–December 2026) will cover Wegovy and Zepbound for eligible beneficiaries with qualifying BMI and health conditions at a $50 monthly copay.
- The BALANCE Model beginning in January 2027 will allow participating Part D plans to cover GLP-1s for weight management on an ongoing basis.
- The Part D out-of-pocket cap of $2,100 in 2026 limits your total annual spending on covered drugs, which can provide meaningful protection if you take expensive GLP-1 medications for a covered condition.
- Always check your plan's formulary, and talk to your doctor about whether prior authorization or step therapy may be required.
For the most current information on coverage and eligibility, visit Medicare.gov or call 1-800-MEDICARE (1-800-633-4227). Your local SHIP can also provide free, personalized guidance.